Leveraging Genetic Determinants of Prostate-Specific Antigen Levels Towards Improving Prostate Cancer Screening

Linda Kachuri[1,2,3], Thomas J. Hoffmann[1,4], Yu Jiang[2], Sonja I. Berndt[5], John P. Shelley[6], Kerry Schaffer[7], Mitchell J. Machiela[5], Neal D. Freedman[5], Wen-Yi Huang[5], Shengchao A. Li[5], Ryder Easterlin[8], Phyllis J. Goodman[9], Cathee Till[10], Ian Thompson[11], Hans Lilja[12,13], Stephen K. Van Den Eeden[14], Stephen Chanock[5], Christopher A. Haiman[15,16], David V. Conti[15,16], Robert J. Klein[17], Jonathan D. Mosley[4,18], Rebecca E. Graff[1]*, John S. Witte[1,2,3,19]*

Affiliations:

1. Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA
2. Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA
3. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
4. Institute of Human Genetics, University of California San Francisco, San Francisco, CA, USA
5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
6. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA
7. Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
8. Biological and Medical Informatics, University of California San Francisco, San Francisco, CA, USA
9. Fred Hutchinson Cancer Research Center, Seattle, WA, USA
10. SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
11. CHRISTUS Santa Rosa Medical Center Hospital, San Antonio, TX, USA
12. Departments of Laboratory Medicine, Surgery, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
13. Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden
14. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
15. Center for Genetic Epidemiology, Department of Population and Preventive Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
16. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
17. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
18. Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
19. Departments of Biomedical Data Science and Genetics (by courtesy), Stanford University, Stanford, CA, USA

* Joint corresponding authors:

Rebecca E. Graff
Department of Epidemiology and Biostatistics
Mission Hall: Global Health & Clinical Sciences Building
550 16th Street, 2nd Floor, Box #0560
San Francisco, CA 94158
Email: Rebecca.Graff@ucsf.edu

John S. Witte
Department of Epidemiology and Population Health
Alway Building, Suite M121
300 Pasteur Drive
Stanford, CA 94305
Email: jswitte@stanford.edu

ABSTRACT

Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. We investigated whether accounting for genetic determinants of variation in PSA that is not due to cancer has potential to improve screening utility. Our multi-ancestry genome-wide meta-analysis of 95,768 men discovered 128 PSA-associated variants (P<5×10^{-8}), 82 of which were novel. A genome-wide polygenic score for PSA (PGS$_{PSA}$) explained 7.08-9.61% of PSA variation in external, multi-ancestry validation cohorts. Diagnostic decisions in men of European ancestry based on PSA values adjusted using PGS$_{PSA}$ would have avoided 31% of negative prostate biopsies, but also resulted in 12% fewer biopsies in prostate cancer cases, mostly in patients with Gleason score <7 tumors. Genetically adjusted PSA was more predictive of aggressive prostate cancer (odds ratio (OR)=3.44, P=6.2×10^{-14}; AUC=0.755) than unadjusted PSA (OR=3.31, P=1.1×10^{-16}; AUC=0.738), and improved detection of aggressive disease when combined with a prostate cancer PGS (AUC: 0.786 vs. 0.712, P=7.2×10^{-4}) in a multi-ancestry sample of 106 cases and 23,667 controls. We also detected PSA-related selection bias that distorts genetic associations with prostate cancer and hinders risk prediction. Our findings provide a roadmap towards personalizing cancer biomarkers and screening.

INTRODUCTION

Prostate-specific antigen (PSA) is a serine protease produced by the prostate gland and encoded by the kallikrein-3 (*KLK3*) gene[1,2]. Its primary function is to enable the release of motile sperm by degrading gel-forming seminal proteins[1,3]. PSA is secreted by normal prostate epithelial tissue, and when this basal layer becomes disrupted by a tumor, greater PSA concentrations are released into circulation[1,2]. PSA levels can also rise due to local prostatic inflammation or infection, benign prostatic hyperplasia, older age, and increased prostate volume[2,4,5]. There is an established inverse relationship between body mass index (BMI) and PSA levels, but it remains unclear whether it is due to decreased androgenic signaling in obese men or hemodilution[6,7]. Low PSA levels thus do not rule out prostate cancer and PSA elevation is not necessarily indicative of a tumor[8].

PSA testing for prostate cancer detection has been used for over 20 years despite controversy surrounding its value. Some argue that PSA testing sufficiently reduces the burden of death from prostate cancer to warrant widespread implementation[9]. However, the long-term risk of lethal prostate cancer remains low, especially in men with PSA below the age-specific median[10,11]. This has led others to question whether the modest mortality benefits outweigh the costs of overdiagnosing and subsequently overtreating indolent disease[12-14]. Between 20 and 60% of prostate cancers detected using PSA testing are estimated to be overdiagnoses, although estimates vary by age group and definition of overdiagnosis[15-17]. As a result, non-lethal prostate cancers are often treated with therapies that can involve substantial side effects[15,16]. The two sides of the debate left the United States Preventive Services Task Force unable to give definitive advice regarding PSA screening for prostate cancer. Its Grade C recommendation indicates that the choice to undergo screening should be an individual one[18]. Clinical guidelines in Canada and the United Kingdom similarly advise against population-level screening[19,20].

One avenue for refining the predictive value of PSA screening for prostate cancer detection is using a more personalized approach. Genetic factors account for over 40% of the variation in PSA levels[21-23]. Our group previously identified 40 independent loci in the largest genome-wide association study (GWAS) of PSA levels to date[23]. Accounting for variability in PSA due to underlying genetics would increase the cancer-related relative variation in PSA, thereby improving its predictive value for prostate cancer. An earlier study using just four PSA-associated variants showed that genetic correction of PSA reclassified 3% of participants to warranting biopsy and 3% to avoiding biopsy[24]. Incorporating additional genetic predictors of PSA variation therefore has potential to transform PSA testing toward reducing overdiagnosis-related morbidity and improving detection of lethal disease.

To maximize the utility of personalized PSA testing, it will be critical to distinguish variants associated with constitutive PSA levels from those that increase the risk of prostate cancer. Studies have identified many shared loci, including the KLK family of genes on chromosome 19q13.33 and pan-cancer susceptibility regions in 5p15.33, 8q24.21, and 10q26.1[23-27]. Because individuals who are genetically predisposed to higher PSA levels are also likely to be screened for prostate cancer more frequently, they are also more likely to receive a prostate cancer diagnosis. As a result, it is possible that GWAS of prostate cancer capture signals for both disease risk and benign PSA elevation.

We present findings from the Precision PSA study, an extensive exploration of the genetics of PSA levels. First, we develop a polygenic score for PSA variation based on a new large GWAS meta-analysis of PSA levels in men without prostate cancer. Following the external validation of this score, we demonstrate how genetic adjustment of PSA levels can improve clinical decision-making related to biopsy and detection of aggressive prostate cancer. In parallel, we provide evidence that PSA-related screening bias influences prostate cancer GWAS and that correction for this bias improves prediction of prostate cancer endpoints. Taken together, our work advances the understanding of the genetic architecture of PSA variation and provides a novel framework for the clinical translation of these findings.

RESULTS

The study design and analytic strategy of the Precision PSA study is illustrated in **Figure 1**. We meta-analyzed results from a previously published GWAS in the Kaiser Permanente Genetic Epidemiology Research in Adult Health and Aging (GERA) cohort[23] with newly conducted GWAS in the UK Biobank (UKB), the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, BioVU from the Vanderbilt University Medical Center, and the Malmö Diet and Cancer Study (MDCS). All discovery analyses were conducted in individuals never having been diagnosed with prostate cancer who had PSA values ≤10 ng/mL **(see Methods)**. A total of 95,768 individuals were included in the GWAS meta-analysis. Across all contributing studies, individuals of predominantly European ancestry comprised the largest subgroup (N_{EUR}=85,824), followed by participants of African ancestry (N_{AFR}=3,509), East Asian ancestry (N_{EAS}=3,337), and Hispanic/Latino individuals ($N_{HIS/LAT}$=3,098).

Genetic Architecture of PSA Variation

To assess sensitivity to underlying modeling assumptions, the heritability (h^2) of PSA levels was investigated in multiple datasets using several methods **(see Methods)**. In the UKB, h^2 was estimated based on PSA values abstracted from clinical records for 26,491 men of predominantly European ancestry, 54.6% of whom had multiple PSA measurements. Median PSA across all available values was 2.35 ng/mL **(Supplementary Figure 1)**. Longitudinal PSA measurements summarized by the median value for each individual had higher h^2 than subject-specific random intercepts derived from linear mixed models **(Supplementary Table 1)**. Using the median, estimated PSA heritability was h^2=0.41 (95% CI: 0.36-0.46) based on GCTA[28] and h^2=0.30 (95% CI: 0.26-0.33) based on LDAK[29,30] (using common (MAF≥0.01) variants with imputation INFO>0.80 for both). GCTA estimates were higher than LDAK estimates across all genetic relatedness matrix (GRM) configurations, but these differences attenuated when restricting to genotyped variants.

Applying LDAK to GWAS summary statistics from the same 26,491 UKB subjects produced similar heritability estimates (h^2=0.35, 0.28-0.43) to GRM results **(Supplementary Table 1)**. Heritability estimates based on other GWAS-based methods were lower, ranging from h^2=0.21 (0.15-0.26) using linkage disequilibrium (LD) score regression to h^2=0.25 (0.21-0.30) using a related high-definition likelihood approach[31]. Since LDAK produced more consistent results in GRM and GWAS summary statistics-based analyses, it was applied to the European ancestry GWAS meta-analysis of PSA levels (N_{EUR}=85,824), yielding h^2=0.30 (95% 0.29-0.31) **(Figure 2)**. Sample sizes for non-European ancestry populations were too small to produce reliable heritability estimates.

Discovery of Novel PSA-Associated Loci

Looking at individual studies, genome-wide analyses of PSA levels in the UKB identified 29 index variants with P<5×10⁻⁸ (using LD clumping (r^2<0.01) within ±10 Mb windows). Six of these variants were independent of previously reported signals in GERA[23]: rs58235267 (*OTX1*) in 2p15; rs79625619 (*THADA*) in 2p21; rs9275602 in the HLA region; rs6506878 (*SALL3*) in 18q23; rs2150165 (*CBFA2T2*) in 20q11.21; and rs186347618 (*TEX11*) in Xq13.1 **(Figure 2; Supplementary Table 2)**. Novel genome-wide significant associations with PSA were not detected in the other, smaller, contributing studies.

In the full Precision PSA study, the fixed effects multi-ancestry meta-analysis of 95,768 men from five studies identified 128 index variants (P<5.0×10⁻⁸, LD r^2<0.01 within ±10 Mb windows) across 90 broadly defined regions corresponding to chromosomal cytobands **(Figure 3; Supplementary Table 3)**. The strongest associations were observed in known PSA genes[23,24,26,27], such as *KLK3* in 19q13.33 (rs17632542, P=3.2×10⁻⁶³⁸), 10q26.12 (rs10886902, P=8.2×10⁻¹¹⁸), *MSMB* in 10q11.23 (rs10993994, P=7.3×10⁻⁸⁷), *NKX3-1* in 8p21.2 (rs1160267, P=6.3×10⁻⁸³), *CLPTM1L* in 5p15.33 (rs401681, P=7.0×10⁻⁵⁴), and *HNF1B* in 17q12 (rs10908278, P=2.1×10⁻⁴⁶). Of the 128 index variants, 82 were independent (LD r^2<0.01) of previously reported[23] PSA associations in GERA. They mapped to 56 cytobands where genome-wide significant signals for PSA have not previously been detected. Novel associations discovered in the UKB became stronger in

the meta-analysis: *TEX11* (rs62608084, $P=1.7\times10^{-24}$); *THADA* (rs11899863, $P=1.7\times10^{-13}$); *OTX1* (rs58235267, $P=4.9\times10^{-13}$); *SALL3* (rs71279357, $P=1.8\times10^{-12}$); and *ST6GAL1* (rs12629450, $P=2.6\times10^{-10}$) **(Supplementary Table 3)**. Additional novel findings in the meta-analysis included *CDK5RAP1* in 20q11.21 (rs291671, $P=1.2\times10^{-18}$), *LDAH* in 2p24.21 (rs10193919, $P=1.5\times10^{-15}$), *ABCC4* in 13q32.1 (rs61965887, $P=3.7\times10^{-14}$), *INKA2* in 1p13.2 (rs2076591, $P=2.6\times10^{-13}$), *SUDS3* in 12q24.23 (rs1045542, $P=1.2\times10^{-13}$), *FAF1* in 1p32.3 (rs12569177, $P=3.2\times10^{-13}$), *JARID2* in 6p22.3 (rs926309, $P=1.6\times10^{-12}$), *GPC3* in Xq26.2 (rs4829762, $P=5.9\times10^{-12}$), *EDA* in Xq13.1 (rs2520386, $P=4.2\times10^{-11}$), and *ODF3* in 11p15.5 (rs7103852, $P=1.2\times10^{-9}$) **(Supplementary Table 3)**.

In the European ancestry meta-analysis ($N_{EUR}=85,824$), 96 of the 128 PSA index variants reached genome-wide significance, compared with three in the East Asian ancestry analysis (*KLK3*: rs2735837, rs374546878; *MSMB*: rs10993994; $N_{EAS}=3,337$), two in the Hispanic/Latino meta-analysis (*KLK3*: rs17632542, rs2735837; $N_{HIS/LAT}=3,098$), and only one (*FGFR2*: rs10749415; $N_{AFR}=3,509$) in the meta-analysis of results from African ancestry men **(Supplementary Table 4)**. Effect sizes from the European ancestry meta-analysis were modestly correlated with effect sizes from the Hispanic/Latino meta-analysis (Spearman's $\rho=0.48$, $P=1.1\times10^{-8}$) and African ancestry meta-analysis ($\rho=0.27$, $P=2.0\times10^{-3}$), but less so with estimates in East Asian individuals ($\rho=0.16$, $P=0.068$) **(Supplementary Figure 2)**. It worth noting that comparisons of correlations across ancestries are confounded by differences in sampling error, which is expected to be higher in populations with smaller sample sizes.

Cochran's Q indicated evidence of heterogeneity ($P_Q<0.05$) for 12 out of 128 index variants, four of which had effects on PSA in different directions across ancestry-specific meta-analyses: rs58235267 (*OTX1*), rs1054713 (*KLK1*), rs10250340 (*EIF4HP1*), and rs7020681 (*SLC35D2*) **(Supplementary Table 5)**. To further explore ancestry-specific signals, we applied MR-MEGA[32], which partitions heterogeneity in SNP effect sizes into components that are correlated with ancestry and residual variation. This meta-analysis identified 119 genome-wide significant index variants, 115 of which also attained $P<5.0\times10^{-8}$ using the standard fixed-effects approach **(Supplementary Table 5)**. Only one variant detected by MR-MEGA mapped to a new PSA-associated region (rs291812 in 5q15). It exhibited the strongest association with PSA in men of East Asian ancestry ($P_{EAS}=1.2\times10^{-6}$) **(Supplementary Table 6)**. Ancestry-related allelic heterogeneity was observed for 18 variants ($P_{Het-Anc}<0.05$), 8 of which were also detected by Cochran's Q.

Since the fixed-effects meta-analysis evaluated and discovered a larger number of PSA-associated variants than MR-MEGA, the predicted functional consequences of the 128 variants detected with the former approach were explored using CADD[33] and expression quantitative trait loci (eQTL) from prostate tissue in GTEx v8 and whole blood in eQTLGen[34]. A total of 16 out of 128 variants had CADD scores >13 (corresponding to the top 5% most deleterious substitutions), which included 10 new signals: rs10193919 (*LDAH*) in 2p24.21; rs7732515 in 5q14.3 ($P=3.5\times10^{-14}$); rs11899863 (*THADA*); rs58235267 (*OTX1*); rs926309 (*JARID2*); rs4829762 (*GPC3*), rs13268 ($P=1.6\times10^{-10}$), a missense variant in *FBLN1*; rs78378222 ($P=2.8\times10^{-10}$) in *TP53*, rs3760230 ($P=2.8\times10^{-8}$) in *SMG6*; and rs712329 ($P=2.0\times10^{-8}$) in *SLC25A21* **(Supplementary Table 7)**.

A total of 61 variants had significant (FDR<0.05) effects on gene expression, including 15 prostate tissue eQTLs for 17 eGenes, 55 blood eQTLs for 185 eGenes, and 9 eQTLs with effects in both tissues **(Supplementary Table 7)**. Notable prostate eGenes among PSA loci included *RUVBL1*, a chromatin-remodeling factor that has diverse cellular functions, such as modulating transcription of MYC and β-catenin and pro-inflammatory responses via NF-κB[35]. Two eGenes were identified for rs10193919: *LDAH* in prostate and blood tissues and *HS1BP3* in blood. *LDAH* promotes cholesterol mobilization in macrophages, which has been linked to prostate cancer and hearing loss[36], and *HS1BP3* plays a role in lymphocyte activation. The lead variant in 11p15.5 (rs7103852) had 7 target eGenes in blood, including *ODF3*, which maintains the elastic structures part of the sperm tail[37], as well as *IFITM2* and *IFITM3*, interferon-induced antiviral proteins.

Impact of PSA-Related Selection Bias on Prostate Cancer GWAS

To characterize the overlap between genetic loci involved in regulation of PSA levels and prostate cancer susceptibility, we obtained GWAS summary statistics from the PRACTICAL consortium[38]. Of the 128 lead PSA variants, 58 (45%) were associated with prostate cancer risk at the Bonferroni-corrected threshold ($p<0.05/128$) in the PRACTICAL multi-ancestry GWAS **(Supplementary Table 8)**. The PSA-increasing allele was the risk-increasing allele for 53 out of 58 Bonferroni-significant variants. Next, we investigated whether index event bias, a type of selection bias, could partly explain these shared genetic signals[39,40] **(see Methods; Figure 4)**. Since prostate cancer detection often hinges on PSA elevation, genetic factors resulting in higher constitutive PSA levels may appear to increase disease risk because of more frequent screening, resulting in biased signals for prostate cancer susceptibility.

The method by Dudbridge et al.[39] generated a positive estimate of the index event bias correction factor (b=1.144, 95% CI: 1.143-1.144) from a regression of prostate cancer log odds ratios (OR) on PSA coefficients for a set of LD-pruned variants in European ancestry subjects **(Supplementary Table 9)**. Using multi-ancestry summary statistics for PSA and prostate cancer yielded similar estimates (b=1.104), although these should be interpreted cautiously due to LD differences across populations. Sensitivity analyses using SlopeHunter[41], which attempts to cluster pleiotropic variants separately from those associated with the selection trait only, produced attenuated estimates (b=0.476, 95% CI: 0.213-0.740).

After applying the Dudbridge estimate to recover unbiased associations with prostate cancer, the number of lead PSA variants associated with prostate cancer in European ancestry subjects decreased from 52 to 34 **(Figure 5; Supplementary Table 8)**. For six of the PSA variants that remained associated with prostate cancer, the effect of the PSA-increasing allele changed from increasing to decreasing for prostate cancer risk: rs17632542 (*KLK3*: OR_{adj}=0.89, P_{adj}=2.7×10⁻¹²), rs2735837 (*KLK3*: OR_{adj}=0.94, P_{adj}=2.1×10⁻⁴), rs7065158 (*EIF2S3*, OR_{adj}=0.97, P_{adj}=1.0×10⁻⁵), rs9325569 (*WDR11*: OR_{adj}=0.96, P_{adj}=1.9×10⁻⁶), rs7206309 (16q23.1: OR_{adj}=0.96, P_{adj}=8.3×10⁻⁶), and rs10466455 (11p13: OR_{adj}=0.97, P_{adj}= 9.7×10⁻⁵). We also evaluated how correction for PSA-related selection bias impacts associations between prostate cancer risk variants and disease risk.

Of the 209 independent prostate cancer risk variants ($P<5.0×10^{-8}$) selected from the PRACTICAL European ancestry meta-analysis using LD clumping ($r^2<0.01$), 93 (45%) remained genome-wide significant after bias correction, and 126 (60%) were associated at $P<1.0×10^{-6}$ **(Figure 5; Supplementary Table 10)**. Prior to bias correction, the smallest effect size was log(OR)=0.0415. After correction, there were 39 variants with bias-corrected |log(OR)|<0.0415. Notably, rs76765083 (*KLK3*) remained genome-wide significant, but reversed direction. Correcting for index event bias using SlopeHunter retained 150 variants (72%) at the genome-wide significant level (**Supplementary Table 10**).

Development and Validation of the PSA Genetic Score (PGS$_{PSA}$)

We considered two approaches for constructing a polygenic score for PSA: 1) clumping and thresholding and 2) the genome-wide Bayesian PRS-CSx algorithm[42,43] **(see Methods)**. The first score was comprised of the 128 independent index variants with $P<5.0×10^{-8}$ from the multi-ancestry meta-analysis (PGS$_{128}$). The second score was generated from ancestry-specific GWAS summary statistics, where the posterior effect sizes for each variant were inferred under coupled continuous shrinkage priors across populations (PGS$_{CSx}$)[42,43]. Each PGS was validated in the Prostate Cancer Prevention Trial (PCPT) and Selenium and Vitamin E Cancer Prevention Trial (SELECT), both of which were excluded from the discovery GWAS (see **Supplementary Figure 3** for ancestry composition and **Methods** for details on ancestry assignment).

In the pooled PCPT sample that included all ancestries (n=5883), PGS$_{CSx}$ was more predictive of baseline PSA levels (β per SD increase = 0.186, P=3.3×10⁻¹¹²) than PGS$_{128}$ (β=0.168, P=1.6×10⁻⁹⁸) **(Figure 6; Supplementary Table 11)**. PGS$_{CSx}$ accounted for 8.13% of variation in baseline PSA levels in the pooled PCPT sample compared to 7.16% explained by PGS$_{128}$. The genome-wide approach outperformed clumping

and thresholding in 5725 participants of predominantly European (EUR≥0.80) ancestry (PGS$_{CSx}$: β=0.194, P=1.7×10^{-115}; PGS$_{128}$: β=0.169, P=5.3×10^{-98}) **(Supplementary Table 11)**. The sample sizes for other ancestry groups were limited in PCPT. Neither PGS$_{128}$ nor PGS$_{CSx}$ reached nominal significance in 103 men with intermediate European and African ancestry (0.20<AFR/EUR<0.80) or in 55 men of predominantly East Asian ancestry (EAS≥0.80). Both genetic scores were associated with baseline PSA in all age groups in the pooled sample, although their effects attenuated in participants aged 70 or older **(Supplementary Figure 4)**.

SELECT offered a larger validation cohort in which to assess PGS performance across a wider ancestry spectrum **(Figure 6; Supplementary Table 11)**. In the pooled sample (n=25,917), PGS$_{CSx}$ was more robustly associated with baseline PSA levels (β=0.258, P=1.3×10^{-619}) than PGS$_{128}$ (β=0.207, P=6.7×10^{-505}). PGS$_{CSx}$ was also more predictive than PGS$_{128}$ in men of European ancestry (β$_{PGS}$=0.283, P=5.5×10^{-610}; n=22,253), accounting for 10.94% of trait variation compared to 8.78% for PGS$_{128}$. Both scores were substantially less predictive in other ancestries, but PGS$_{CSx}$ showed an improvement over PGS$_{128}$ in most groups **(Figure 6; Supplementary Table 11)**. In men with intermediate AFR/EUR ancestry (n=1763), PGS$_{CSx}$ explained 4.22% of PSA variation (β=0.157, P=4.8×10^{-19}), compared to 3.32% (β=0.146, P=3.0×10^{-15}) for PGS$_{128}$. The largest improvements were observed in men of predominantly East Asian (n=257) ancestry (PGS$_{CSx}$: β=0.258, P=5.9×10^{-7}; PGS$_{128}$ β=0.136, P=0.012) and intermediate EAS/EUR ancestry (n=321; PGS$_{CSx}$: β=0.315, P=5.2×10^{-12}; PGS$_{128}$ β=0.229, P=8.5×10^{-8}). In the African ancestry stratum (AFR≥0.80; n=1173), PGS$_{128}$ (β=0.163, P=8.2×10^{-11}) was more predictive than PGS$_{CSx}$ (β=0.098, P=8.0×10^{-6}). This was also observed in the AFR pooled group (AFR and AFR/EUR: n=2936), where PGS$_{128}$ explained 3.36% of trait variation compared to 3.11% for PGS$_{CSx}$ **(Supplementary Table 11)**.

We also examined PGS associations with temporal trends in pre-diagnostic PSA: velocity, calculated using log(PSA) values at two time points, and doubling time in months **(see Methods for details)**. In men who experienced an increase in PSA (SELECT pooled sample: n=14,908), both PGS$_{CSx}$ and PGS$_{128}$ were associated with less rapid velocity (PGS$_{CSx}$: β= -4.06×10^{-4}, P=3.7×10^{-5}; PGS$_{128}$: β= -3.30×10^{-4}, P=1.3×10^{-4}) and longer doubling time (PGS$_{CSx}$: β=10.41, P=1.9×10^{-8}; PGS$_{128}$: β=8.47, P=1.8×10^{-7}) **(Supplementary Table 12)**. In men who experienced a decrease in PSA between the first and last time point (SELECT pooled sample: n=6970), PGS$_{128}$ was not associated with velocity, and PGS$_{CSx}$ was only suggestively associated with slowing PSA decline (β=5.02×10^{-4}, P=0.068). The same pattern of results was observed in PCPT, with higher PGS$_{CSx}$ values conferring less rapid changes in PSA **(Supplementary Table 12)**.

Given the superior overall performance of PGS$_{CSx}$ in pooled analyses of PCPT and SELECT, this score (now referred to as PGS$_{PSA}$) was applied to calculate genetically adjusted PSA values (PSA^G). For each subject, baseline or earliest pre-randomization PSA values were adjusted based on their PGS$_{PSA}$ relative to the PGS$_{PSA}$ population mean **(see Methods for details)**. Genetically adjusted PSA^G and unadjusted baseline PSA were strongly correlated in PCPT (Pearson's r=0.841, 95% CI: 0.833 – 0.848) and SELECT (r=0.854, 0.851 – 0.857). The number of participants with PSA^G>4 ng/mL, a commonly used threshold for further diagnostic testing, increased from 0 to 24 in PCPT and from 5 to 413 in SELECT **(Figure 6)**, reflecting the preferential selection of subjects with low PSA into these trials.

Impact of PSA-Related Bias on Genetic Risk Score Associations

We fit the most recent 269-variant prostate cancer polygenic score (PGS$_{269}$)[38] in the UKB and examined its association with PGS$_{PSA}$ in male participants of European ancestry without PSA data (who were excluded from the GWAS). There was a strong positive relationship between the two genetic scores in prostate cancer cases (β=0.190, P=2.3×10^{-96}; n=11,568) and controls (β=0.236, P<10^{-700}; n=152,884) **(Figure 7, Supplementary Table 13)**. Re-fitting PGS$_{269}$ using risk allele weights with Dudbridge bias correction (PGS$_{269}$^{adj}) substantially attenuated this association in cases (β$_{adj}$=0.029, P=2.7×10^{-3}) and controls (β$_{adj}$=0.052, P=2.2×10^{-89}). SlopeHunter weights (PGS$_{269}$$^{adj-S}$) also reduced the magnitude of association (cases: β$_{adj-S}$=0.130, P=1.1×10^{-45}; controls: β$_{adj-S}$=0.169, P<10^{-700}), but less so than Dudbridge correction.

To further characterize the impact of PSA-related bias, we examined PGS_{269} associations with prostate cancer in 3673 cases and 2363 biopsy-confirmed cancer-free controls of European ancestry from the GERA cohort. Bias-corrected PGS_{269}^{adj} had a larger magnitude of association with prostate cancer (OR for top decile=3.63, 95% CI: 3.01-4.37) than PGS_{269} (OR=2.71, 2.28-3.21) and yielded a higher area under the curve based on 10-fold cross-validation (AUC: 0.685 vs. 0.677, P=3.91×10^{-3}) **(Supplementary Table 14)**. The impact of bias correction was more pronounced for tumors with Gleason score ≥7 (PGS_{269}^{adj} AUC=0.692 vs. PGS_{269} AUC=0.678, P=1.91×10^{-3}). Effect sizes for PGS_{269}^{adj-S} were larger than the estimates observed for PGS_{269}, but slightly attenuated compared to PGS_{269}^{adj} for prostate cancer overall (OR=3.30, 2.76-3.95) and Gleason score ≥7 tumors (OR=3.02, 2.43-3.75). We also note that AUC estimates in GERA are inflated because this study was included in the prostate cancer GWAS used to develop PGS_{269}[38].

In case-only analyses, PGS_{PSA} and PGS_{269} were both inversely associated with Gleason score, illustrating how screening bias increases the detection of tumors with a less aggressive profile and decreases the likelihood of identifying high-grade disease **(Supplementary Table 15)**. Men with higher PGS_{PSA} were less likely to have tumors with Gleason score 7 (OR per SD increase=0.79, 0.76-0.83) or Gleason ≥8 (OR=0.71, 0.64-0.81) than Gleason ≤6. Patients in the top decile of PGS_{269} were nearly 30% less likely to be diagnosed with Gleason ≥8 disease (OR=0.72, 0.54-0.96) than Gleason ≤6 disease, but this relationship was attenuated after bias correction (PGS_{269}^{adj}: OR=0.94, 0.75-1.17). SlopeHunter was slightly less effective at correcting for screening bias (Gleason ≥8 vs. Gleason ≤6: OR per SD=0.90, 0.80-1.00) than the Dudbridge approach (OR per SD=0.95, 0.85-1.06).

Genetic Adjustment of PSA Values Affects Eligibility for Prostate Biopsy

Adjustment of PSA values using PGS_{PSA} results in appreciable shifts in the PSA distribution, so we examined the potential of PSA^G to improve decisions related to performing prostate biopsy in prostate cancer cases and cancer-free controls from GERA participants who underwent a biopsy. Using PGS_{PSA}, we adjusted each person's PSA value immediately prior to biopsy and examined re-classification at age-specific thresholds used for recommending biopsy in Kaiser Permanente: 40-49 years old = 2.5 ng/ml; 50-59 years old = 3.5 ng/ml; 60-69 years old = 4.5 ng/ml; and 70-79 years old = 6.5 ng/ml.

In European ancestry men, mean PSA levels in controls who were biopsied (7.2 ng/mL, n=2363) were higher than in controls who did not have a prostate biopsy (1.5 ng/mL; n=24,811) **(Supplementary Table 16)**. The subset of men who underwent a biopsy was also enriched for genetic predisposition to PSA elevation. Mean values of the standardized PGS_{PSA} were above zero in cases ($\overline{PGS}_{PSA}$ =0.278) and controls ($\overline{PGS}_{PSA}$ =0.934). Among controls, 31.7% were reclassified below the PSA level for recommending biopsy, while 2.5% became eligible for biopsy after genetic adjustment, resulting in a net reclassification index (NRI) of 29.3% **(Figure 8; Supplementary Table 16)**. Among 3673 cases, downward reclassification resulting in PSA^G values below the biopsy referral threshold (n=452, 12.3%) was more prevalent than upward reclassification (n=139, 3.8%). Most of the patients who became ineligible had tumors with Gleason score <7 (n=301, 72%). Downward reclassification was highest among patients aged <65 years (14.6%). In men of predominantly African ancestry, there were few changes in biopsy eligibility among cases (n=392), with 3.1% reclassified upward and 4.6% downward **(Figure 8; Supplementary Table 16)**. Of the 108 biopsy-negative controls (n=75, 69.4%) were reclassified below the referral threshold based on PSA^G, reflecting the high enrichment for predisposition to PSA elevation ($\overline{PGS}_{PSA}$ =1.710). Assuming that eligibility changes in either direction are valued equally, the overall NRI for biopsy was positive in men of European (NRI=0.241) and African ancestry (NRI=0.645), suggesting that PSA^G has some clinical utility in this setting.

Genetic Adjustment of PSA Levels Improves Prostate Cancer Detection

We evaluated the potential utility of genetically adjusted PSA, alone and in combination with prostate cancer PGS_{269}, by examining associations with prostate cancer risk in PCPT (pooled: 335 cases, 5548 controls; European ancestry: 323 cases, 5414 controls). End-of-study biopsies were performed in all PCPT participants, which effectively eliminated potential for misclassification of case status due to undiagnosed,

asymptomatic disease. PGS_{PSA} was not associated with prostate cancer incidence (pooled: OR=1.01, P=0.83), confirming it captures genetic determinants of non-cancer PSA variation. The magnitude of association for genetically adjusted baseline $log(PSA^G)$ (OR per unit increase=1.90, 95% CI: 1.56-2.31) was slightly larger than for baseline $log(PSA)$ (OR=1.88, 1.55-2.29) in European ancestry men, but not in the pooled sample (OR: 1.83 vs 1.85), and the difference in AUC was not statistically significant in either population **(Supplementary Table 17)**. The magnitude of association with prostate cancer was larger for bias-corrected PGS_{269}^{adj} (pooled and European: OR=1.57, 1.40-1.76) than standard PGS_{269} (pooled: OR=1.52, 1.36-1.70; European: OR=1.53, 1.36-1.72) **(Supplementary Table 17)**. The model that included both PGS_{269}^{adj} and PSA^G achieved the best classification in the pooled (AUC=0.686) and European ancestry (AUC=0.688) populations, and outperformed PGS_{26}^{adj} (pooled: AUC=0.656, P_{AUC}=7.5×10^{-4}; European: AUC=0.658, P_{AUC}=1.4×10^{-3}). The correlation between PGS_{269} and PSA^G (β=0.029) was lower than the correlation between PGS_{269} and PSA (β=0.072), making the former predictors more orthogonal **(Supplementary Figure 5)**. Bias corrected PGS_{269}^{adj} was not correlated with PSA (β=-0.001), but it was modestly correlated with PSA^G (β=0.019), which may explain why including both PSA^G and PGS_{269}^{adj} did not yield a significant improvement over PSA^G and PGS_{269} (pooled AUC: 0.686 vs. 0.685, P_{AUC}=0.87).

The benefit of genetic adjustment of PSA was most evident for detection of aggressive prostate cancer, defined as Gleason score ≥7, PSA ≥ 10 ng/mL, T3-T4 stage, and/or distant or nodal metastases. In PCPT, PSA^G conferred an approximately 3-fold increase in risk (pooled: OR=2.87, 1.98-4.65, AUC=0.706; European: OR=2.99, 1.95-4.59, AUC=0.711) compared to an approximately 1.5-fold increase in risk observed for PGS_{269}^{adj} (pooled: OR=1.55, 1.23-1.95, AUC=0.651; European: OR=1.55, 1.22-1.96, AUC=0.657; **Figure 9; Supplementary Table 18)**. The combined model with PSA^G and PGS_{269}^{adj} achieved an AUC of 0.726 (European: AUC=0.734) for aggressive tumors, but showed lower discrimination for non-aggressive disease (pooled and European: AUC=0.681; **Supplementary Table 19).** In case-only analyses, PSA^G (pooled: OR=2.06, 1.23-3.45) and baseline PSA (pooled: OR=1.81, 1.12-3.10) were associated with a higher likelihood of aggressive compared to non-aggressive tumors, whereas PGS_{269} (pooled: OR=0.91, P=0.54) and PGS_{269}^{adj} (OR=0.97, P=0.85) were not **(Supplementary Table 20)**.

In SELECT, associations with risk of prostate cancer overall **(Supplementary Table 21),** aggressive prostate cancer **(Figure 9; Supplementary Table 22)**, and non-aggressive disease **(Supplementary Table 23)** in the pooled and European ancestry analyses replicated the results observed for PSA^G in PCPT. Associations with incident prostate cancer for PSA^G (OR=2.15, 0.82-5.62) were attenuated compared to unadjusted PSA (OR=2.60, 1.03-6.54) in men of East Asian ancestry (EAS pooled: 13 cases and 544 controls; **Supplementary Table 21)**. This was also observed for men of African ancestry (AFR pooled: 88 cases and 2733 controls; PSA: OR=3.63, 2.54-5.30), although the effect size for PSA^G derived using PGS_{128} (OR=3.37, 2.38-4.78) was larger than for PSA^G based on PGS_{CSx} (OR=2.68, 1.94-3.69), consistent with the larger proportion of variation in PSA explained by PGS_{128} than PGS_{CSx} in this population. Models for prostate cancer including PSA^G were calibrated in the pooled and in European ancestry subjects, while in the African ancestry subgroup PSA^G tended to inaccurately estimate risk in several upper deciles **(Supplementary Figure 7)**.

The largest improvement in discrimination provided by PSA^G (OR=3.81, 2.62-5.54; AUC=0.777) relative to baseline PSA (OR=3.40, 2.34-4.93; AUC=0.742, P_{AUC}=0.026) and to PGS_{269} (OR=1.76, 1.41-2.21; AUC=0.726; P_{AUC}=0.057) was observed for aggressive tumors in men of European ancestry (106 cases and 23,667 controls). In the pooled African ancestry sample (18 cases and 2733 controls), PSA^G calculated using PGS_{128} (OR=2.96, 1.43-6.12), but not using PGS_{CSx} (OR=2.48, 1.24-4.97), was more predictive of aggressive prostate cancer than unadjusted PSA (OR=2.82, 1.33-5.99; **Supplementary Table 22)**. The best model for aggressive prostate cancer included PSA^G and PGS_{269}^{adj} for pooled (AUC=0.788, 95% CI: 0.744-0.831) and European ancestry populations (AUC=0.804, 0.757-0.851), but for African ancestry unadjusted PSA and PGS_{269} without bias correction achieved the highest AUC of 0.828 (95% CI: 0.739-0.916). For aggressive prostate cancer **(Supplementary Figure 8),** PSA^G showed better calibration than PSA in pooled and European ancestry groups, but not in the pooled African ancestry sample.

DISCUSSION

Serum PSA is the most widely used biomarker for prostate cancer detection, although concerns with specificity, and to a lesser degree sensitivity, have limited formal adoption of PSA testing for population-level screening. With the goal of improving its accuracy, we conducted a multi-ancestry GWAS of PSA levels in 95,768 men without prostate cancer, established the heritability of PSA variation to be between 30% to 40%, and identified 128 genome-wide significant PSA index variants. Most importantly, our study provides new evidence that genetic determinants of PSA levels can be leveraged to personalize and enhance the utility of PSA screening.

Leveraging genetic profiles to personalize clinical biomarkers enables the translation of GWAS discoveries into clinical practice. This concept has been referred to as "de-Mendelization," since it is essentially Mendelian randomization in reverse – instead of relying on genetically-predicted biomarker values to investigate causal relationships, subtracting the component of variance attributed to genetic factors for non-causal predictive biomarkers can maximize the residual disease-related signal and yield appreciable improvement in disease prediction [44,45]. While doing so has been alluded to in previous work on PSA genetics[24,46] and other biomarkers[44,47,48], the value of this approach for detecting clinically meaningful disease and reducing unnecessary diagnostic testing has not been demonstrated prior to this study.

Normalization of each person's PSA value was achieved using a personalized adjustment factor based on their PGS_{PSA}. For those with above average PGS_{PSA}, reflecting an inherited predisposition to PSA elevation, their measured PSA values were adjusted downward, whereas those with lower PGS_{PSA} received an upward correction. Genetic adjustment produces clinically meaningful shifts in PSA distribution in several scenarios. Relying on genetically adjusted PSA values would reduce biopsies in men who are later found to be cancer-free, although this may be accompanied by some undesirable loss of sensitivity. While reclassifying cases to not receive biopsy is a concern, most such reclassifications occurred among patients with less aggressive disease characteristics (Gleason <7), a group susceptible to overdiagnosis[14]. Genetically adjusted PSA values also significantly improve classification of disease status compared to baseline PSA. In PCPT and SELECT, we showed that PSA^G was a more robust predictor of aggressive prostate cancer, relative to both baseline PSA and an established 269-variant prostate cancer risk score. Furthermore, we demonstrated that GWAS-identified prostate cancer risk variants, including those in PGS_{269}, are affected by a systematic PSA-related selection bias. Correcting for this bias represents an extension of the PSA de-Mendelization paradigm that improves PGS_{269} performance.

Distinguishing variants that influence prostate cancer detection via PSA screening from genetic signals for prostate carcinogenesis has implications not only for deciphering susceptibility mechanisms, but also for the development of more effective genetic risk prediction models. However, differentiating between these classes of variants using standard methods, like conditional analysis, may not be feasible. Prostate cancer detection directly depends on PSA testing, while PSA screening activities are partly influenced by genetic factors affecting constitutive PSA variation. Modelling the bias arising from this complex dependency on a genome-wide scale[39,41] suggest that the magnitude of PSA-related selection bias may be substantial. Using summary statistics from the largest published GWAS of prostate cancer[38], we observed that 45-72% of independent index variants remained genome-wide significant after bias correction. This reduction in signal does not imply that many prostate cancer GWAS associations are false, but rather that bias-corrected effect sizes more accurately capture the contribution of these variants to disease risk, without conflation with detection.

This aligns with our findings that prediction of prostate cancer status improves proportionally to the extent that both PSA and PGS_{269} are de-noised of genetic signals for PSA elevation that are not attributable to prostate cancer. Adjusting risk allele weights proved effective for PGS_{269} because this score is comprised of fine-mapped variants that already have a high posterior probability of being causal. The improvement following correction for PSA-related bias was observed in all analyses, but was most pronounced in men with high PSA. The relative improvement in AUC achieved by PGS_{269}^{adj} compared to PGS_{269} was highest in GERA

participants who underwent a biopsy, where controls had markedly higher PSA levels than in the remainder of the cohort. However, this trend was also observed in PCPT, a starkly different clinical trial population of men with baseline PSA ≤3 ng/mL[8,49]. Furthermore, the magnitude of association with aggressive prostate cancer was consistently larger for PGS_{269}^{adj} than the standard PGS_{269} in both PCPT and SELECT, which enrolled men with PSA ≤4 ng/mL[50]. This is intuitive considering that bias correction decreases the correlation with PGS_{PSA}, which is associated with a higher likelihood of low-grade disease.

A key conclusion of our study is that risk stratified and personalized screening for prostate cancer will require parallel efforts to elucidate the genetic architecture of prostate cancer susceptibility and PSA variation in individuals without disease. Our GWAS of PSA levels advances these efforts with the discovery of 82 PSA-associated variants that are novel based on conservative LD criteria. Many novel variants map to genes involved in embryonic development, epigenetic regulation, and chromatin organization, including *DNMT3A*, *OTX1*, *CHD3*, *JARID2*, *HMGA1*, *HMGA2*, and *SUDS3*. *DNMT3A* is a methyltransferase that regulates imprinting and X-chromosome inactivation, and has been studied extensively in the context of clonal hematopoiesis and hematologic cancers[51], as well as height[52]. One of the highest CADD scores, indicative of TF-binding activity, was detected for rs58235267 in *OTX1*, which regulates the development of cortical, sensory, and mammary organs. *CHD3* is also involved in chromatin remodeling during development and plays a role in suppressing herpes simplex virus infection[53]. There were several PSA-associated variants in genes related to infection and immunity, including *HLA-A*; *ST6GAL1*, involved in IgG N-glycosylation[54]; *KLRG1*, which regulates NK cell function and IFN-γ production[55]; and *FUT2*, which affects ABO precursor H antigen presentation in mucosal tissues and confers susceptibility to multiple viral and bacterial infections[56,57].

Several new PSA signals mapped to genes involved in reproductive processes, which may reflect non-cancer function of PSA in liquefying seminal fluid. *TEX11* on Xq13.1 is preferentially expressed in male germ cells and early spermatocytes. Mutations in *TEX11* cause meiotic arrest and azoospermia, and this gene also regulates homologous chromosome synapsis and double-strand DNA break repair[58]. *ODF3* encodes a component of sperm flagella fibers and has also been linked to regulation of platelet count and volume[59]. *PLAC1* is involved in placenta development, although there is some evidence that it is differentially expressed among healthy, hyperplastic, and neoplastic prostate tissues[60].

Although our GWAS was restricted to men without prostate cancer, several cancer susceptibility genes were among the newly identified PSA-associated loci, including a pan-cancer risk variant in *TP53* (rs78378222)[61,62], as well as signals in *TP63*, *GPC3*, and *THADA*. We cannot rule out the presence of undiagnosed prostate cancer, but the prevalence of undetected tumors is unlikely to be high enough to have an appreciable impact on GWAS results. Pervasive pleiotropy and an omnigenic architecture[63] may explain the diverse functions of PSA-associated genes. As GWAS sample sizes and power increase, many of the newly identified PSA loci are broadly implicated in disease susceptibility by regulating inflammation, epigenetic regulation, and growth factor signaling. There is also evidence that even established tumor suppressor genes have pleiotropic effects. For instance, *TP53*, *GPC3*, and *THADA* have been linked to anthropometric traits and obesity via dysregulation of cell growth and metabolism[64-67]. Distinct p63 isoforms play a crucial role in epithelial and craniofacial development, as well as apoptosis of male germ cells and spermatogenesis[68,69]. Mutations in *GPC3* cause Simson-Golabi-Behmel syndrome, which is characterized by overgrowth with visceral and skeletal abnormalities and excess risk of embryonic tumors[70].

Our investigation of index event bias is not without limitations. This approach assumes that the same bias correction factor applies to all variants, although signals at some loci may be more biased than others. A fundamental but unrealistic assumption of the Dudbridge method is that direct genetic effects on PSA levels and prostate cancer susceptibility are not correlated[39]. Violations of this assumption would over-attribute shared genetic signals to selection bias. SlopeHunter relaxes this assumption[41], resulting in an attenuated bias estimate. A potential limitation of SlopeHunter is its reliance on clustering to distinguish PSA-specific from pleiotropic variants[41], with small or poorly separated clusters resulting in unstable bias estimates. Analyses of PGS_{269} with SlopeHunter weights suggest it may under-correct for selection bias. Despite the

difficulty in quantifying its magnitude, both methods detected a non-zero PSA-related bias in prostate cancer GWAS. Disentangling of PSA and prostate cancer associations with a greater certainty and resolution will require experimental approaches, such as CRISPR screens and massively parallel reporter assays.

Another limitation is that the magnitude of biopsy reclassification reported here may be specific to GERA and Kaiser Permanente clinical guidelines. Estimates in cancer-free men may be especially biased since GERA controls were part of the PSA discovery GWAS (30% of total GWAS sample size). To mitigate this bias, we used an out-of-sample mean PGS_{PSA} value to calculate the genetic adjustment factor, but this may be insufficient. Since it is unlikely that men with low PSA would have been biopsied, there are also limited opportunities to increase biopsy eligibility in this dataset. Controls who underwent a biopsy had higher PSA and PGS_{PSA} values than other GERA controls, so downward correction of PSA values was to be expected. The same constraint applies to cases, most of whom already had PSA values at or above the biopsy referral cutoff (although some procedures were performed before the current Kaiser Permanente guidelines were implemented). In contrast, genetic adjustment tended to increase PSA values in PCPT and SELECT since these trials selected men with low PSA. Despite these limitations, our findings still indicate that genetically adjusted PSA may reduce overdiagnosis and overtreatment.

Our PGS-based approach offers a contemporary update to the first application of PSA genetic correction by Gudmundsson et al.[24] by leveraging a more comprehensive genetic predictor, while retaining straightforward calculation of the genetic correction factor. Increasing the specificity of a biomarker that has already been shown to have clinical utility is more efficient than introducing new algorithms and would have lower adoption barriers since both patients and clinicians are already familiar with PSA. However, this approach is not without challenges. Analytic choices, such as selecting an optimal PGS algorithm and a reference population for obtaining the mean PGS_{PSA} value, are not trivial. The choice of reference population would not affect the AUC, but would impact the magnitude of the correction factor and clinical decisions based on absolute PSA values. Furthermore, any new biomarker would require prospective validation in real-world settings to identify populations who would benefit the most from genetic adjustment and characterize barriers to implementation. In our study, assessment of clinical utility was underpowered for all ancestries except European. Additional barriers are primary care physician and urologist familiarity with GWAS and genetic risk scores, as well as patient education about the nature of genetic testing. Genetically adjusted PSA should also be evaluated in conjunction with other procedures used for prostate cancer detection, such as targeted MRI, and to explore the potential of PSA^G to refine selection of participants into trials of screening protocols.

Our study highlights the importance and challenge of developing a PGS that achieves adequate performance across all ancestries. We emphasize that genetic adjustment of PSA should only be considered if PGSPSA shows robust performance in the target population. If it does not, the accuracy of PSA as a screening test will be negatively impacted. Our PGS_{PSA} was dominated by association signals detected in men of European ancestry, who comprised over 90% of the analytic sample. As a result, genetic correction of PSA values did not improve detection of prostate cancer in other ancestry groups, where PGS_{PSA} accounted for a small proportion of PSA variation. Worse performance of PGS_{CSx} in men of predominantly African ancestry compared to the PGS_{128} may reflect our choice of the 'meta' estimation procedure, which does not require an additional dataset for hyperparameter tuning, but is expected to be less accurate[42]. GWAS efforts in larger and more diverse cohorts are currently under way and will greatly augment the catalog of PSA-associated variants and their utility.

Future lines of inquiry should assess whether genetically adjusted PSA levels improve prediction of prostate cancer mortality and investigate a range of PSA-related biomarkers. Our study focused on total PSA, although serum PSA exists in multiple forms, and studies have suggested that PSA derivatives, such as the ratio of free to total PSA and pro-PSA, may have higher specificity for prostate cancer detection[71,72]. We also showed that PGS_{PSA} was associated with measures of temporal PSA change, such as doubling time and velocity, but these associations should be interpreted with caution. As others have noted[73], these metrics only assess change between two time points and may not capture PSA trajectories that are meaningful for

disease detection. There is also a lack of clinical guidelines for PSA kinetics in the context of screening for prostate cancer. Regardless, we believe that genetic adjustment may improve the accuracy of any heritable PSA biomarker.

In summary, by detecting genetic variants associated with non-prostate cancer PSA variation, we developed a novel PGS$_{PSA}$ that measures the contribution of common genetic variants to a man's inherent PSA level. Genetic determinants of PSA provide an avenue for refining prostate cancer GWAS signals by mitigating selection bias due to PSA screening, and for improving disease prediction. Moreover, we used the PGS$_{PSA}$ to calculate genetically adjusted, personalized PSA levels that provide clinically meaningful improvements in prostate cancer diagnostic outcomes. These results illustrate a roadmap for incorporating genetic factors into PSA screening for prostate cancer and expanding this potentially valuable approach to other diagnostic biomarkers.

METHODS

Study Populations and Phenotyping

Genome-wide association analyses of PSA levels were conducted in individuals never diagnosed with prostate cancer to avoid reverse causation. Men with a history of surgical resections of the prostate were also excluded in studies for which this information was available. All analyses were limited to PSA values ≤10 ng/mL, which corresponds to low-risk prostate cancer based on the D'Amico prostate cancer risk classification system[74], and PSA>0.01 ng/mL, to ensure that subjects had a functional prostate not impacted by surgery or radiation.

The UK Biobank (UKB) is a population-based prospective cohort of over 500,000 individuals aged 40-69 years at enrollment in 2006-2010 with genetic and phenotypic data[75]. Health-related outcomes were ascertained via individual record linkage to national cancer and mortality registries and hospital in-patient encounters. For a subset of UKB participants, PSA values were abstracted from primary care records that were linked to genetic and phenotypic data. Field code mappings used to identify PSA values included any serum PSA measure except for free PSA or ratio of free to total PSA **(Supplementary Table 25)**.

The Kaiser Permanente Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort used in this analysis has been previously described in Hoffmann et al[23]. Briefly, prostate cancer status was ascertained from the Kaiser Permanente Northern California Cancer Registry, the Kaiser Permanente Southern California Cancer Registry, or through review of clinical electronic health records. PSA levels were abstracted from Kaiser Permanente electronic health records from 1981 through 2015.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a randomized trial that enrolled approximately 155,000 participants between November 1993 and July 2001. PLCO was designed to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74[76]. Men randomized to the screening arm of the trial underwent annual screening with PSA for six years and digital rectal exam (DRE) for four years[76]. These analyses were limited to men with a baseline PSA measurement who were randomized to the screening arm of the trial (N=29,524). Men taking finasteride at the time of PSA measurement, individuals who were outliers based on ancestry-specific principal components were excluded from analysis.

The Vanderbilt University Medical Center BioVU resource is a synthetic derivative biobank linked to deidentified electronic health records[77]. Analyses were based on PSA levels that were measured as part of routine clinical care. For men with multiple PSA measurements, the median PSA was used.

The Malmö Diet and Cancer Study (MDCS) is a population-based prospective cohort study that recruited men and women aged between 44 and 74 years old who were living in Malmö, Sweden between 1991 and 1996 to investigate the impact of diet on cancer risk and mortality[78]. These analyses included men from the MDCS who were not diagnosed with prostate cancer as of December 2014 and had available genotyping and baseline PSA measurements[78].

The Prostate Cancer Prevention Trial (PCPT) was a phase III randomized, double-blind, placebo-controlled trial of finasteride for prostate cancer prevention that began in 1993[8]. PCPT randomly assigned 18,880 men aged 55 years or older who had a normal DRE and PSA level ≤3 ng/mL to either finasteride or placebo. For subjects who had multiple pre-randomization PSA values, the earliest value was selected. Cases included all histologically confirmed prostate cancers detected during the 7-year treatment period and tumors that were detected by the end-of-study prostate biopsy. Our analyses included the subset of PCPT participants that was genotyped on the Illumina Infinium Global Screening Array (GSAMD) 24v2-0 array.

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a phase III randomized, placebo-controlled trial of selenium (200 µg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac-α-tocopheryl acetate) supplementation for prostate cancer prevention[50]. Between 2001 and 2004, 34,888

eligible subjects were randomized. The minimum enrollment age was 50 years for African American men and 55 years for all other men[50]. Additional eligibility requirements included no prior prostate cancer diagnosis, ≤4 ng/mL of PSA in serum, and a DRE not suspicious for cancer. For subjects who had multiple pre-randomization PSA values, the earliest value was selected. Our analyses included a subset of SELECT participants genotyped on the Illumina Infinium Global Screening Array (GSAMD) 24v2-0 array.

Study-Specific Quality Control and Association Analyses

Standard genotyping and quality control (QC) procedures were implemented in each participating study. Prior to meta-analysis we applied variant-level QC filters included low imputation quality (INFO<0.30) and minor allele frequency (MAF)<0.005. Sample-level QC filtered based on discordant genetic and self-reported sex and low call rate and removed one sample from each pair of first-degree relatives. Detailed descriptions of the genotyping platforms, imputation methods, QC, and ancestry assignment for each study are provided in the **Supplementary Note**.

Study-specific GWAS phenotypes and covariates are reported in **Supplementary Table 26** and in Hoffmann et al.[23] for previously published analyses in GERA. Genome-wide association analyses performed linear regression analyses of log(PSA) as the outcome, using age and genetic ancestry principal components (PCs) as the minimum set of covariates. For most studies with longitudinal data, multiple PSA measures per individual were summarized by taking the median PSA value **(Supplementary Table 26)**. Sensitivity analyses were conducted in the UKB comparing this approach to a GWAS of individual-specific random effects derived from fitting a linear mixed model to repeated log(PSA) values with the same covariates.

Heritability of PSA Levels Attributed to Common Variants

Heritability of PSA levels was estimated using individual-level data and GWAS summary statistics. UKB subjects with available PSA and genetic data were analyzed using Linkage Disequilibrium Adjusted Kinships (LDAK) v5.1[29] and GCTA v1.93[28], following the approach previously implemented in the GERA cohort[23]. Genetic relationship matrices were filtered to ensure that no pairwise relationships with kinship estimates>0.05 remained. Heritability was estimated using common (MAF≥0.01) LD-pruned (r^2<0.80) variants with imputation INFO>0.80. We implemented the LDAK-Thin model using the recommended GRM settings (INFO>0.95, LD r^2<0.98 within 100 kb) and the same parameters as GCTA for comparison (LD r^2<0.80, INFO>0.80). For both methods, sensitivity analyses were conducted using more stringent GRM settings (kinship=0.025, genotyped variants).

Summary statistics from GWAS results based on the same set of UKB participants (26,491 subjects) and from a European ancestry GWAS meta-analysis (85,824 subjects) were analyzed using LDAK, LD score regression (LDSR)[79], and an extension of LDSR using a high-definition likelihood (HDL) approach[31]. For LDSR we used the default panel comprised of variants available in HapMap3 with weights computed in 1000 Genomes v3 EUR subjects and in-house LD scores computed in UKB European ancestry subjects[62]. The baseline linkage disequilibrium (BLD)-LDAK model was fit using precomputed tagging files calculated in UKB GBR (white British) individuals for HapMap3 variants from the LDSR default panel. HDL analyses were conducted using the UKB-derived panel restricted to high-quality imputed HapMap3 variants[31]. All GWAS summary statistics had sufficient overlap with the reference panels, not exceeding the 1% missingness threshold for HDL and 5% missingness threshold for LDAK and LDSR.

Genome-Wide Meta-Analysis

Each ancestral population was analyzed separately, and GWAS summary statistics were combined via meta-analysis **(Figure 1)**. We first used METAL[80] to conduct a fixed-effects inverse-variance-weighted meta-analysis in each ancestral group. We then meta-analyzed the ancestry-specific results. Meta-analysis results were processed using clumping to identify independent association signals by grouping variants based on linkage disequilibrium within specific windows. Clumps were formed around index variants with the lowest

genome-wide significant ($P<5×10^{-8}$) meta-analysis p-value. All other variants with LD r^2 >0.01 within a ± 10Mb window were considered non-independent and assigned to that lead variant. Since over 90% of the meta-analysis consisted of predominantly European ancestry subjects, clumping was performed using 1000 Genomes (1000G) EUR and UKB reference panels, which yielded concordant results. We confirmed that LD among the resulting lead variants did not exceed r^2=0.05 using a merged 1000G ALL reference panel.

We first examined heterogeneity in the multi-ancestry fixed effects meta-analysis results using Cochran's Q statistic. To assess heterogeneity specifically due to ancestry we applied MR-MEGA[32], a meta-regression approach for aggregating GWAS results across diverse populations. Summary statistics from each GWAS were meta-analyzed using MR-MEGA without combining by ancestry first. The MR-MEGA analysis was performed across four axes of genetic variation derived from pairwise allele frequency differences, based on the recommendation for separating major global ancestry groups. Index variants from the MR-MEGA analysis were selected using the same clumping parameters as described above (LD r^2 <0.01 within ± 10Mb window), based on the merged 1000G ALL reference panel. For each variant, we report two heterogeneity p-values: one that is correlated with ancestry and accounted for in the meta-regression ($P_{Het-Anc}$) and the residual heterogeneity that is not due to population genetic differences ($P_{Het-Res}$).

PSA Genetic Score (PGS$_{PSA}$) Development and Validation

We implemented two strategies for generating a genetic score for PSA levels. In the first approach, we selected 128 variants that were genome-wide significant ($P<5×10^{-8}$) in the multi-ancestry meta-analysis and were independent (LD r^2 <0.01 within ± 10Mb window) in 1000G EUR and (LD r^2<0.05) 1000G ALL populations (PGS$_{128}$). Each variant in PGS$_{128}$ was weighted by the meta-analysis effect size estimated using METAL. As an alternative strategy to clumping and thresholding, we fit a genome-wide score using the PRS-CSx algorithm[42,43], which takes GWAS summary statistics from each ancestry group as inputs and estimates posterior SNP effect sizes under coupled continuous shrinkage priors across populations (PGS$_{CSx}$). Analyses were conducted using pre-computed population-specific LD reference panels from the UKB, which included 1,287,078 HapMap3 variants that are available in both the UKB and 1000 Genomes Phase 3.

We calculated a single trans-ancestry PGS that can be applied to all participants in the target cohort, rather than optimizing a PGS within each ancestry group. This approach is more robust to differences in genetic ancestry assignments across studies and does not require separate testing and validation datasets for parameter tuning each ancestry group [42]. To facilitate this type of analysis, PRS-CSx provides a --meta option that integrates population-specific posterior SNP effects using an inverse-variance-weighted meta-analysis in the Gibbs sampler[42,43]. The global shrinkage parameter was set to φ=0.0001. PRS-CSx was run on the intersection of variants that were in the LD reference panel and had imputation quality (INFO>0.90), resulting in 1,058,163 variants in PCPT and 1,071,268 variants in SELECT. Since PRS-CSx only considers autosomes, chrX variants that were included in PGS$_{128}$ were added to PGS$_{CSx}$ separately, when output files from each chromosome produced by the PLINK --score command were concatenated.

The predictive performance of PGS$_{CSx}$ and PGS$_{128}$ was evaluated in two independent cancer prevention trials that were not included in the meta-analysis: PCPT and SELECT. Analyses were conducted in the pooled sample for each cohort, which included individuals of all ancestries who passed quality control filters **(see Supplementary Note).** Ancestry-stratified analyses were conducted for clusters with n>50 with available genetic ancestry principal components (PC's). Ancestry scores were computed with SNPWEIGHTS[81]. Individuals with ancestry scores ≥0.80 for a single group were assigned to clusters for predominantly European (EUR), West African (AFR) and East Asian (EAS) ancestry. Admixed individuals with intermediate ancestry scores for at least one group were assigned to separate clusters: 0.20<EUR/AFR<0.80 or 0.20<EUR/EAS<0.80. Pooled analyses were adjusted for 10 within-cluster PC's and global ancestry proportions (AFR, EAS).

Index Event Bias Analysis

Index event bias occurs when subjects are selected based on the occurrence of an event or specific criterion. This is analogous to the direct dependence of one phenotype on another, as in the commonly used example of cancer survival[40]. Due to unmeasured confounding, this dependence can induce correlations between previously independent risk factors among those selected[39,40]. Genetic effects on prostate cancer can be viewed as conditional on PSA levels, since elevated PSA typically triggers diagnostic investigation. Genetic factors resulting in higher constitutive PSA levels may also increase the likelihood of prostate cancer detection due to more frequent testing **(Figure 4)**. This selection mechanism could bias prostate cancer GWAS associations by capturing both direct genetic effects on disease risk and selection-induced PSA signals. In the GWAS setting, methods using summary statistics have been developed to estimate and correct for this bias[39,41]. Although typically derived assuming a binary selection trait, these methods are still applicable to selection or adjustment based on quantitative phenotypes[39,82]. In this study, we conceptualized PSA variation as the selection trait and prostate cancer incidence as the outcome trait **(Figure 4)**.

We applied the method described in Dudbridge et al.[39], which tests for index event bias and estimates the corresponding correction factor (b) by regressing genetic effects on the selection trait (PSA) against their effects on the subsequent trait (prostate cancer), with inverse variance weights: $w = 1/(SE_{PrCa})^2$. Summary statistics for prostate cancer were obtained from the most recent prostate cancer GWAS from the PRACTICAL consortium[38]. Sensitivity analyses were performed using SlopeHunter[41], an extension of the Dudbridge approach that allows for direct genetic effects on the index trait and subsequent trait to be correlated. For both methods, analyses were conducted using relevant summary statistics and 127,906 variants pruned at the recommended threshold[39] (LD r^2<0.10 in 250 kb windows) with MAF ≥0.05 in the 1000G EUR reference panel. After merging the pruned 1000G variants with each set of summary statistics, variants with large effects, ($|\beta|$>0.20) on either log(PSA) or prostate cancer, were excluded. Raw bias estimates (b_{raw}) were adjusted for regression dilution using a modified version of the SIMEX algorithm. The resulting estimate (b) was used as a correction factor to recover unbiased genetic effects for each variant: $\beta'_{PrCa} = \beta_{PrCa} - b * \beta_{PSA}$, where β_{PSA} is the per-allele effect on log(PSA), and β_{PrCa} is the log(OR) for prostate cancer.

The impact of the bias correction was assessed in three ways. First, genome-wide significant prostate cancer index variants were selected from the European ancestry PRACTICAL GWAS meta-analysis (85,554 cases and 91,972 controls) using clumping (LD r^2<0.01 within 10 Mb)[38]. We tabulated the number of variants that remained associated at P<5×10^{-8} after bias correction. Next, we fit genetic scores for PSA and prostate cancer in European ancestry UKB subjects, limiting to an out-of-sample set of participants that was not included in the PSA or prostate cancer GWAS (11,568 cases and 152,884 controls). We compared the correlation between the PGS for PSA (PGS$_{PSA}$), comprised of 128 lead variants, and the 269-variant prostate cancer risk score fit with original risk allele weights (PGS$_{269}$) and with weights corrected for index event bias (PGS$_{269}$^{adj}). To allow adjustment for genetic ancestry PCs and genotyping array, associations between the two scores were estimated using linear regression models. Next, we examined associations for each genetic score (PGS$_{269}$, PGS$_{269}$^{adj}, PGS$_{269}$$^{adj-S}$) with prostate cancer in a subset of GERA participants who underwent a biopsy. Since GERA controls were include in the PSA GWAS meta-analysis, AUC estimates and corresponding bootstrapped 95% confidence intervals were obtained using 10-fold cross-validation. We also examined PGS associations with Gleason score, a marker of disease aggressiveness, which was not available in the UK Biobank. Multinomial logistic regression models with Gleason score ≤6 (reference), 7, and ≥8 as the outcome were fit for each score in 4584 cases from the GERA cohort.

Application of Genetically Adjusted PSA for Biopsy Referral and Prostate Cancer Detection

In addition to evaluating PGS$_{PSA}$ directly, we examined genetically corrected PSA values calculated for individual i as follows: $PSA_i^G = {PSA_i}/{a_i}$, where a_i is a personalized adjustment factor derived from

PGS_{PSA}[23,24]. Since genetic effects were estimated for log(PSA), a_i for correcting PSA in ng/mL was derived as: $a_i = \exp(PGS_i) \Big/ \exp(\overline{PGS})$, where $\overline{PGS}$ is estimated directly in controls without prostate cancer or obtained from an external control population[23,24]. We see that $a_i > 1$ when an individual has a higher multiplicative increase in PSA than the sample average due to their genetic profile, resulting in a lower genetically adjusted PSA compared to the observed value ($PSA_i^G < PSA_i$).

We evaluated the potential utility of PGS_{PSA} in two clinical contexts. First, we quantified the impact of using PSA_i^G on biopsy referrals by examining reclassification at age-specific PSA thresholds used in the Kaiser Permanente health system. Analyses were conducted in GERA participants with information on biopsy date and outcome, comprised of prostate cancer cases not included in the PSA GWAS and controls that were part of the PSA GWAS. In order to use the same normalization factor for both cases and controls while mitigating bias due to control overlap with the PSA discovery GWAS, a_i for GERA subjects was calculated by substituting $\overline{PGS}$ from out-of-sample UK Biobank controls (n=152,884). Upward classification occurred when $PSA_i^G > PSA_i \cap PSA_i^G > ref$, where ref was the biopsy referral threshold. Downward classification was defined as: $PSA_i^G < PSA_i \cap PSA_i^G < ref$. The net reclassification index (NRI) was used to summarize clinical utility: $NRI = P(up|case) - P(down|case) + P(down|control) - P(up|control)$.

Next, we assessed the performance of risk prediction models for prostate cancer overall, aggressive prostate cancer, and non-aggressive prostate cancer in PCPT and SELECT. Since both studies were excluded from the PSA GWAS meta-analysis, a_i and PSA_i^G for subjects in PCPT and SELECT were calculated using $\overline{PGS}$ observed in each respective dataset. Consistent with the PGS_{PSA} validation analysis, pooled analyses included individuals of all ancestries who passed quality control filters. To facilitate ancestry-stratified analyses in SELECT, especially for aggressive disease, we combined AFR and AFR/EUR clusters into a single group (AFR pooled) and similarly pooled EAS and EAS/EUR (EAS pooled). Aggressive prostate cancer was defined as Gleason score ≥7, PSA ≥ 10 ng/mL, T3-T4 stage, and/or distant or nodal metastases. We compared AUC estimates for logistic regression models using the following predictors, alone and in combination: baseline PSA, genetically adjusted baseline PSA (PSA^G), PGS_{PSA}, prostate cancer risk score with original weights (PGS₂₆₉)[38] and weights corrected for index event bias (PGS₂₆₉^{adj}).

DATA AVAILABILITY

The research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte). UK Biobank data are publicly available by request from https://www.ukbiobank.ac.uk. To maintain individuals' privacy, data on the GERA cohort are available by application to the Kaiser Permanente Research Bank (researchbank.kaiserpermanente.org).

Informed consent was obtained from all study participants. UK Biobank received ethics approval from the Research Ethics Committee (REC reference: 11/NW/0382) in accordance with the UK Biobank Ethics and Governance Framework. Approval for other studies contributing data to the Precision PSA consortium was obtained from each of the participating institutional research ethics review boards.

FUNDING ACKNOWLEDGEMENTS

The Precision PSA study is supported by funding from the National Institutes of Health (NIH) National Cancer Institute (NCI) under award number R01CA241410 (PI: JSW). Additionally, LK is supported by funding from National Cancer Institute (K99CA246076) and REG is supported by a Young Investigator Award from the Prostate Cancer Foundation. This work was supported by research grants from the NIH National Institute of General Medical Sciences (NIGMS) under award number R01GM130791 (PI: JDM). HL is supported in part by NIH/NCI by a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], prostate cancer SPORE grant [P50-CA92629], Swedish Cancer Society (Cancerfonden 20 1354 PjF), and General Hospital in Malmö Foundation for Combating Cancer. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD026880 and NIH/NCI funding (R01CA175491, R01CA244948; PI: RJK).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

DISCLOSURES

JSW is a non-employee, cofounder of Avail Bio. HL is named on a patent for intact PSA assays and a patent for a statistical method to detect prostate cancer that is licensed to and commercialized by OPKO Health. HL receives royalties from sales of the test and has stock in OPKO Health.

References

1. Balk, S.P., Ko, Y.J. & Bubley, G.J. Biology of prostate-specific antigen. *J Clin Oncol* **21**, 383-91 (2003).
2. Lilja, H., Ulmert, D. & Vickers, A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. *Nat Rev Cancer* **8**, 268-78 (2008).
3. Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. *J Clin Invest* **76**, 1899-903 (1985).
4. Pinsky, P.F. *et al.* Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. *Urology* **68**, 352-6 (2006).
5. Lee, S.E. *et al.* Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. *Urology* **71**, 395-8 (2008).
6. Grubb, R.L., 3rd *et al.* Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cancer Epidemiol Biomarkers Prev* **18**, 748-51 (2009).
7. Harrison, S. *et al.* Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. *Cancer Causes Control* **31**, 431-449 (2020).
8. Thompson, I.M. *et al.* Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* **98**, 529-34 (2006).
9. Schroder, F.H. *et al.* Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* **360**, 1320-8 (2009).
10. Vickers, A.J. *et al.* Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. *BMJ* **346**, f2023 (2013).
11. Kovac, E. *et al.* Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *JAMA Netw Open* **3**, e1919284 (2020).
12. Jemal, A. *et al.* Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. *JAMA* **314**, 2054-61 (2015).
13. Sammon, J.D. *et al.* Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. *JAMA* **314**, 2077-9 (2015).
14. Gulati, R., Inoue, L.Y., Gore, J.L., Katcher, J. & Etzioni, R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. *J Natl Cancer Inst* **106**, djt367 (2014).
15. Telesca, D., Etzioni, R. & Gulati, R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. *Biometrics* **64**, 10-9 (2008).
16. Welch, H.G. & Black, W.C. Overdiagnosis in cancer. *J Natl Cancer Inst* **102**, 605-13 (2010).
17. Vickers, A.J. *et al.* Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. *BMC Med* **12**, 26 (2014).
18. Force, U.S.P.S.T. *et al.* Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA* **319**, 1901-1913 (2018).
19. Bell, N. *et al.* Recommendations on screening for prostate cancer with the prostate-specific antigen test. *CMAJ* **186**, 1225-34 (2014).
20. Tikkinen, K.A.O. *et al.* Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. *BMJ* **362**, k3581 (2018).
21. Bansal, A. *et al.* Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. *J Clin Endocrinol Metab* **85**, 1272-6 (2000).
22. Pilia, G. *et al.* Heritability of cardiovascular and personality traits in 6,148 Sardinians. *PLoS Genet* **2**, e132 (2006).
23. Hoffmann, T.J. *et al.* Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. *Nat Commun* **8**, 14248 (2017).
24. Gudmundsson, J. *et al.* Genetic correction of PSA values using sequence variants associated with PSA levels. *Sci Transl Med* **2**, 62ra92 (2010).
25. Benafif, S., Kote-Jarai, Z., Eeles, R.A. & Consortium, P. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). *Cancer Epidemiol Biomarkers Prev* **27**, 845-857 (2018).
26. Wiklund, F. *et al.* Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. *Prostate* **69**, 419-27 (2009).

27. Kim, S., Shin, C. & Jee, S.H. Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies. *Gene* **556**, 199-205 (2015).

28. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* **88**, 76-82 (2011).

29. Speed, D., Holmes, J. & Balding, D.J. Evaluating and improving heritability models using summary statistics. *Nat Genet* **52**, 458-462 (2020).

30. Zhang, Q., Prive, F., Vilhjalmsson, B. & Speed, D. Improved genetic prediction of complex traits from individual-level data or summary statistics. *Nat Commun* **12**, 4192 (2021).

31. Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations across human complex traits. *Nat Genet* **52**, 859-864 (2020).

32. Magi, R. *et al.* Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum Mol Genet* **26**, 3639-3650 (2017).

33. Rentzsch, P., Schubach, M., Shendure, J. & Kircher, M. CADD-Splice-improving genome-wide variant effect prediction using deep learning-derived splice scores. *Genome Med* **13**, 31 (2021).

34. Vosa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat Genet* **53**, 1300-1310 (2021).

35. Mao, Y.Q. & Houry, W.A. The Role of Pontin and Reptin in Cellular Physiology and Cancer Etiology. *Front Mol Biosci* **4**, 58 (2017).

36. Currall, B.B. *et al.* Loss of LDAH associated with prostate cancer and hearing loss. *Hum Mol Genet* **27**, 4194-4203 (2018).

37. Egydio de Carvalho, C. *et al.* Molecular cloning and characterization of a complementary DNA encoding sperm tail protein SHIPPO 1. *Biol Reprod* **66**, 785-95 (2002).

38. Conti, D.V. *et al.* Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet* **53**, 65-75 (2021).

39. Dudbridge, F. *et al.* Adjustment for index event bias in genome-wide association studies of subsequent events. *Nat Commun* **10**, 1561 (2019).

40. Paternoster, L., Tilling, K. & Davey Smith, G. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. *PLoS Genet* **13**, e1006944 (2017).

41. Mahmoud, O., Dudbridge, F., Davey Smith, G., Munafo, M. & Tilling, K. A robust method for collider bias correction in conditional genome-wide association studies. *Nat Commun* **13**, 619 (2022).

42. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* **54**, 573-580 (2022).

43. Ge, T. *et al.* Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. *Genome Med* **14**, 70 (2022).

44. Kjaergaard, A.D., Bojesen, S.E., Nordestgaard, B.G., Johansen, J.S. & Smith, G.D. Biomarker de-Mendelization: principles, potentials and limitations of a strategy to improve biomarker prediction by reducing the component of variance explained by genotype. *bioRxiv*, 428276 (2018).

45. Holmes, M.V. & Davey Smith, G. Can Mendelian Randomization Shift into Reverse Gear? *Clin Chem* **65**, 363-366 (2019).

46. Witte, J.S. Personalized prostate cancer screening: improving PSA tests with genomic information. *Sci Transl Med* **2**, 62ps55 (2010).

47. Enroth, S., Johansson, A., Enroth, S.B. & Gyllensten, U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. *Nat Commun* **5**, 4684 (2014).

48. Mohammadi-Shemirani, P. *et al.* A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. *Clin Chem* **65**, 427-436 (2019).

49. Goodman, P.J. *et al.* The prostate cancer prevention trial: design, biases and interpretation of study results. *J Urol* **175**, 2234-42 (2006).

50. Lippman, S.M. *et al.* Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* **301**, 39-51 (2009).

51. Bick, A.G. *et al.* Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature* **586**, 763-768 (2020).

52. Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature* **542**, 186-190 (2017).

53. Arbuckle, J.H. & Kristie, T.M. Epigenetic repression of herpes simplex virus infection by the nucleosome remodeler CHD3. *mBio* **5**, e01027-13 (2014).
54. Shen, X. *et al.* Multivariate discovery and replication of five novel loci associated with Immunoglobulin G N-glycosylation. *Nat Commun* **8**, 447 (2017).
55. Wang, J.M. *et al.* KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection. *J Virol* **87**, 11626-36 (2013).
56. Tian, C. *et al.* Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. *Nat Commun* **8**, 599 (2017).
57. Kachuri, L. *et al.* The landscape of host genetic factors involved in immune response to common viral infections. *Genome Med* **12**, 93 (2020).
58. Yatsenko, A.N. *et al.* X-linked TEX11 mutations, meiotic arrest, and azoospermia in infertile men. *N Engl J Med* **372**, 2097-107 (2015).
59. Astle, W.J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell* **167**, 1415-1429 e19 (2016).
60. Ghods, R. *et al.* High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. *Cancer Immunol Immunother* **63**, 1319-27 (2014).
61. Stacey, S.N. *et al.* A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nat Genet* **43**, 1098-103 (2011).
62. Rashkin, S.R. *et al.* Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. *Nat Commun* **11**, 4423 (2020).
63. Boyle, E.A., Li, Y.I. & Pritchard, J.K. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell* **169**, 1177-1186 (2017).
64. Di Giovannantonio, M. *et al.* Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. *J Med Genet* **58**, 392-399 (2021).
65. Liu, S., Kim, T.H., Franklin, D.A. & Zhang, Y. Protection against High-Fat-Diet-Induced Obesity in MDM2(C305F) Mice Due to Reduced p53 Activity and Enhanced Energy Expenditure. *Cell Rep* **18**, 1005-1018 (2017).
66. Filmus, J. & Capurro, M. The role of glypican-3 in the regulation of body size and cancer. *Cell Cycle* **7**, 2787-90 (2008).
67. Moraru, A. *et al.* THADA Regulates the Organismal Balance between Energy Storage and Heat Production. *Dev Cell* **41**, 72-81 e6 (2017).
68. Vanbokhoven, H., Melino, G., Candi, E. & Declercq, W. p63, a story of mice and men. *J Invest Dermatol* **131**, 1196-207 (2011).
69. Wang, H. *et al.* Transcriptional regulation of P63 on the apoptosis of male germ cells and three stages of spermatogenesis in mice. *Cell Death Dis* **9**, 76 (2018).
70. Neri, G., Gurrieri, F., Zanni, G. & Lin, A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. *Am J Med Genet* **79**, 279-83 (1998).
71. Catalona, W.J. *et al.* Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. *JAMA* **279**, 1542-7 (1998).
72. Loeb, S. *et al.* The prostate health index selectively identifies clinically significant prostate cancer. *J Urol* **193**, 1163-9 (2015).
73. Vickers, A.J. & Brewster, S.F. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. *Br J Med Surg Urol* **5**, 162-168 (2012).
74. D'Amico, A.V. Risk-based management of prostate cancer. *N Engl J Med* **365**, 169-71 (2011).
75. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209 (2018).
76. Andriole, G.L. *et al.* Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* **360**, 1310-9 (2009).
77. Roden, D.M. *et al.* Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther* **84**, 362-9 (2008).
78. Klein, R.J. *et al.* Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. *Eur Urol* **61**, 471-7 (2012).
79. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5 (2015).

80. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
81. Chen, C.Y. *et al.* Improved ancestry inference using weights from external reference panels. *Bioinformatics* **29**, 1399-406 (2013).
82. Aschard, H., Vilhjalmsson, B.J., Joshi, A.D., Price, A.L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *Am J Hum Genet* **96**, 329-39 (2015).

Figure 1: Overview of the Precision PSA study design. Genome-wide association analyses were first conducted separately in European ancestry (EUR), African ancestry (AFR), East Asian ancestry (EAS) and Hispanic/Latin American (HIS/LAT) men without prostate cancer. Each contributing study and corresponding sample size are listed. Results from the multi-ancestry meta-analysis of 95,768 men was used to develop a genome-wide PSA genetic score (PGS$_{PSA}$) comprised of approximately 1.1 million variants. PGS$_{PSA}$ was validated in two independent cohorts, Prostate Cancer Prevention Trial (PCPT) and Selenium and Vitamin E Cancer Prevention Trial (SELECT), and used to compute genetically adjust PSA values (PSA^G). Downstream analyses examined how using genetically adjusted PSA values influences eligibility for prostate biopsy and evaluated associations with prostate cancer case/control status.

Figure 2: Genome-wide association results and heritability of PSA levels in men of European ancestry.
Panel A) compares heritability (h^2) of PSA variation in men without prostate cancer across estimation methods and data inputs. Analyses were restricted to European ancestry (EUR) individuals as sample sizes in other ancestry groups were too small to produce reliable estimates. In the UK Biobank (UKB), heritability was estimated using GCTA and Linkage Disequilibrium Adjusted Kinships (LDAK)-Thin models from a genetic relatedness matrix (GRM) of common (MAF≥0.01) LD-pruned (r^2<0.80) variants with imputation quality INFO>0.80. These estimates were compared to analyses of GWAS summary statistics from the UK Biobank and the EUR meta-analysis using the baseline linkage disequilibrium LDAK model and a high-definition likelihood (HDL) method by Ning et al [29]. Panel B) shows UK Biobank GWAS results where known PSA loci are labeled with the corresponding cytoband region and new regions are labeled with the nearest gene. Peaks in dark blue include variants in LD (r^2≥0.01) with the lead novel variant.

Figure 3: Multi-ancestry genome-wide association study (GWAS) PSA levels. Results of the GWAS meta-analysis of PSA levels in 96,768 men without prostate cancer are shown in the Manhattan plot. The genome-wide significance threshold of $P<5\times10^{-8}$ is indicated by the solid black line. Known PSA-associated loci are labeled with the corresponding cytoband region. Novel findings are shown in purple. For parsimony, only one index variant with lowest p-value is highlighted in each cytoband. Peaks in dark blue show variants in linkage disequilibrium ($r^2\geq0.01$) with the lead novel variant. The inset circular Manhattan plot provides a close-up view of the highlighted region, where newly discovered genes are labeled in purple, and names of previously reported PSA-associated genes are in black.

Figure 4: PSA-related index event bias. Conceptual diagram depicting how selection on PSA levels induces an association between genetic variant G and U, a composite confounder that captures polygenic and non-genetic factors. This selection induces an association with prostate cancer (PrCa) via path G – U → PrCa (blue dotted line), in addition to the direct G → PrCa effects. Gray dotted lines show that PSA is not only a disease biomarker, but also influences the likelihood of prostate cancer detection by influencing screening behavior. For instance, men with constitutively high levels may undergo more frequent PSA testing. Genetic associations with prostate cancer required for the analysis were obtained from the PRACTICAL GWAS by Conti & Darst et al.[36]

Figure 5: Impact of correction for PSA-related selection bias on genetic associations with prostate cancer.
Associations with prostate cancer were obtained from the PRACTICAL GWAS by Conti et al.[36] for 128 index variants identified using clumping and thresholding ($P<5\times10^{-8}$, linkage disequilibrium $r^2<0.01$) in the PSA GWAS meta-analysis. Panel A) compares effect sizes for prostate cancer (β_{PrCa}) before and after bias correction and panel C) shows the change in -log10(p-value) for prostate cancer for the same 128 variants. Index variants for prostate cancer were selected from the PRACTICAL GWAS by Conti & Darst et al.[36] using the same clumping and thresholding criteria ($P<5\times10^{-8}$, linkage disequilibrium $r^2<0.01$). Associations with PSA levels for 209 prostate cancer risk variants were obtained from our GWAS meta-analysis of PSA levels. The impact of bias correction on prostate cancer effect sizes is shown in panel C) and the corresponding change in -log10(p-value) is visualized in panel D).

Figure 6: Validation of the polygenic score for PSA (PGS_PSA) in two cancer prevention trials. Performance of PGS_PSA was evaluated in the Prostate Cancer Prevention Trial (PCPT) and Selenium and Vitamin E Cancer Prevention Trial (SELECT). Panels A) and B) depict associations with baseline log(PSA) across quantiles of PGS_PSA, comprised of 1,058,163 and 1,071,268 variants in PCPT and SELECT, respectively. Panels C) and D) show effect estimates per standard deviation (SD) increase in the standardized PGS_PSA on baseline log(PSA) in the pooled sample from each study and stratified by ancestry group. Panels E) and F) compare distributions of observed and genetically adjusted PSA values (PSA^G), with the horizontal line at 4 ng/mL corresponding to a PSA threshold commonly used to indicate further diagnostic testing.

Figure 7: Impact of index event bias on polygenic score (PGS) associations. Association between PGS for PSA (PGS_PSA) and PGS for prostate cancer (PGS_269) fit using original weights, as reported in Conti & Darst et al.[36], is compared to PGS_269 fit using weights that have been adjusted for index event bias (PGS_269^adj) using the Dudbridge et al.[39] method. Panel A) visualizes the regression line for the PGS association in cases overlaid on individual data points summarized as hexbins. Panel B) visualizes results of the same regression in controls. Analyses were restricted to European ancestry men in the UK Biobank (UKB) that were not included in the PSA GWAS or prostate cancer GWAS from PRACTICAL.

Figure 8: Genetically adjusted PSA (PSA^G) influences biopsy eligibility. Sankey diagram illustrates changes in PSA values for subjects from the Genetic Epidemiology Research in Adult Health and Aging (GERA) cohort after genetic adjustment and the resulting reclassification at PSA thresholds used to recommend prostate biopsy in Kaiser Permanente. Size of the nodes and flows are proportional to the number of individuals in each category. Prostate cancer cases were stratified by Gleason score categories, where Gleason <7 represents potentially indolent disease. Analyses were conducted separately in GERA participants of predominantly European A) and African B) ancestry.

Figure 9: Associations with risk of aggressive prostate cancer. Comparison of models for aggressive disease, defined as Gleason score ≥7, PSA ≥ 10 ng/mL, T3-T4 stage, and/or distant or nodal metastases in participants from the Prostate Cancer Prevention Trial (PCPT) and Selenium and Vitamin E Cancer Prevention Trial (SELECT). The pooled sample in each cohort combines all ancestry groups. Area under the curve (AUC) estimates are based on adjusted logistic regression models that include age at PSA measurement, randomization arm, the top 10 population-specific genetic ancestry principal components, and two covariates for global African and East Asian ancestry proportions. Odds ratios were estimated per unit increase in log(PSA) and log(PSA^G), and per standard deviation increase in the standardized prostate cancer genetic risk score (PGS_{269}) from Conti & Darst et al.[36]